GO:0004090 carbonyl reductase (NADPH) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004090 describes carbonyl reductase (NADPH) activity, the NADPH-dependent reduction of ketones and aldehydes to secondary alcohols.
• The reaction follows an ordered bi-bi mechanism in which NADPH binds first and NADP+ leaves last, with a catalytic tyrosine and lysine in the active site.
• Human carbonyl reductase 1 (CBR1) is the archetypal enzyme for this activity and can use NADP(H) as a tightly bound prosthetic group.
• CBR1 detoxifies reactive carbonyls, activates or inactivates drugs such as anthracyclines, and modulates prostaglandin and steroid metabolism.
• Flavonoids and other small molecules inhibit CBR1, making the enzyme a target for modulating drug resistance and oxidative stress.
• Engineered carbonyl reductases are used in biocatalysis for chiral alcohol synthesis, including the vibegron intermediate.
Description
Carbonyl reductase (NADPH) activity, encoded by the Gene Ontology term GO:0004090, is a molecular function that catalyzes the reversible reduction of a ketone or aldehyde to the corresponding secondary alcohol using NADPH as the electron donor. This activity is central to carbonyl detoxification, drug metabolism, and the biosynthesis of signaling molecules such as prostaglandins. The reaction is formally described as a secondary alcohol + NADP+ = a ketone + H+ + NADPH, and it is widely distributed across prokaryotes and eukaryotes. In humans, the best-characterized enzyme carrying this activity is carbonyl reductase 1 (CBR1), a member of the short-chain dehydrogenase/reductase (SDR) superfamily. CBR1 is a cytosolic enzyme that reduces a broad range of exogenous and endogenous carbonyl compounds, including quinones, anthracyclines, and prostaglandins. Because of its broad substrate specificity, CBR1 is a key node in redox homeostasis and xenobiotic metabolism. Researchers study GO:0004090 to understand how cells handle oxidative stress, how anticancer drugs are inactivated, and how chiral alcohols can be produced industrially. The activity is also relevant to diseases such as cancer, where CBR1 overexpression contributes to drug resistance, and to metabolic disorders linked to carbonyl stress. This article provides a research-grade overview of the mechanism, genes, regulation, disease links, and experimental methods for studying carbonyl reductase (NADPH) activity.
carbonyl reductase (NADPH) activity At A Glance
| GO ID | GO:0004090 |
|---|---|
| GO term | carbonyl reductase (NADPH) activity |
| Ontology | molecular_function |
| Synonym | aldehyde reductase 1; aldehyde reductase I activity; ALR3; carbonyl reductase activity; NADPH2-dependent carbonyl reductase activity; NADPH-dependent carbonyl reductase activity; nonspecific NADPH-dependent carbonyl reductase activity; prostaglandin 9-ketoreductase activity; secondary-alcohol:NADP+ oxidoreductase activity; xenobiotic ketone reductase activity |
| Major function | NADPH-dependent reduction of ketones and aldehydes to secondary alcohols |
| Reaction | a secondary alcohol + NADP+ = a ketone + H+ + NADPH |
| Cofactor | NADPH (NADP+ as oxidized form); can act as a prosthetic group in CBR1 |
| Representative enzyme | Carbonyl reductase 1 (CBR1), a short-chain dehydrogenase/reductase |
| Subcellular location | Cytosol (for CBR1) |
What Is GO:0004090?
In simple terms, GO:0004090 describes the ability of an enzyme to use NADPH to convert a carbonyl group (a ketone or aldehyde) into an alcohol. The official definition is: Catalysis of the reaction: a secondary alcohol + NADP+ = a ketone + H+ + NADPH. This means the enzyme transfers a hydride from NADPH to the carbonyl carbon, reducing it to a hydroxyl group, while NADP+ is released. The reaction is reversible, but in cells the NADPH/NADP+ ratio strongly favors the reduction direction. The term is classified as a molecular_function in the Gene Ontology and includes synonyms such as aldehyde reductase 1, prostaglandin 9-ketoreductase, and xenobiotic ketone reductase, reflecting its broad substrate range.
Why Is carbonyl reductase (NADPH) activity Important in Cell Biology?
Carbonyl reductase (NADPH) activity is important because it controls the levels of reactive carbonyls that can damage proteins, lipids, and DNA, and it determines the fate of many drugs and signaling molecules. By reducing carbonyls to alcohols, the enzyme generally produces less reactive and more water-soluble products that can be excreted or further metabolized. This activity therefore protects cells from oxidative stress and influences the efficacy of anticancer agents such as daunorubicin and doxorubicin. In addition, the enzyme participates in the metabolism of prostaglandins and steroids, linking it to inflammation and endocrine signaling. Because of its broad substrate range, carbonyl reductase is also a valuable biocatalyst for producing chiral alcohols used in pharmaceuticals.
• Detoxifies reactive carbonyls generated by oxidative stress and lipid peroxidation.
• Inactivates anthracycline anticancer drugs, contributing to chemoresistance in cancer cells.
• Activates or inactivates prostaglandins, affecting inflammation and pain signaling.
• Metabolizes steroids and retinoids, influencing endocrine and developmental pathways.
• Serves as a target for flavonoid inhibitors that modulate its activity.
• Plays a role in the metabolism of xenobiotics, including quinones and ketones.
• Is used in industrial biocatalysis for the synthesis of chiral pharmaceutical intermediates.
• Its dysfunction is linked to carbonyl stress in neurodegeneration and metabolic disorders.
• Provides a model for studying NADPH-dependent oxidoreductases and cofactor binding.
• Enables structure-activity studies of inhibitors and substrate specificity.
What Happens During carbonyl reductase (NADPH) activity?
Substrate binding and cofactor selection
In simple terms: The enzyme first grabs NADPH, the carrier of electrons, and then binds the carbonyl substrate.
Carbonyl reductases follow an ordered bi-bi mechanism in which NADPH binds to the enzyme before the carbonyl substrate. The cofactor is positioned in a Rossmann-fold domain typical of short-chain dehydrogenases/reductases, and the nicotinamide ring is oriented for hydride transfer. In CBR1, NADP(H) can act as a tightly bound prosthetic group rather than a transient cofactor, which influences the enzyme's catalytic cycle. Substrate binding occurs in a hydrophobic cleft that accommodates a wide range of ketones and aldehydes, explaining the broad specificity of the enzyme.
Hydride transfer and carbonyl reduction
In simple terms: A hydride ion is moved from NADPH to the carbonyl carbon, turning the ketone or aldehyde into an alcohol.
The catalytic step involves stereospecific transfer of a hydride from the C4 position of the nicotinamide ring to the carbonyl carbon of the substrate. A conserved tyrosine and lysine in the active site facilitate proton transfer and stabilize the transition state. This reduction converts a ketone to a secondary alcohol or an aldehyde to a primary alcohol, with NADP+ remaining bound until product release. The reaction is reversible, but the high cellular NADPH/NADP+ ratio drives reduction in vivo.
Product release and cofactor recycling
In simple terms: After the alcohol product leaves, NADP+ is released and the enzyme is ready for another round.
Following hydride transfer, the alcohol product is released, and NADP+ dissociates from the enzyme. The enzyme can then bind a new NADPH molecule to initiate another catalytic cycle. In cells, NADPH is regenerated by the pentose phosphate pathway and other dehydrogenases, maintaining the reducing environment needed for continuous carbonyl reduction. The release of NADP+ is often the rate-limiting step, and mutations that affect cofactor affinity can alter catalytic efficiency.
Substrate specificity and physiological roles
In simple terms: The enzyme can act on many different carbonyl compounds, which is why it is involved in so many processes.
Carbonyl reductase (NADPH) activity accepts a wide range of substrates, including quinones, prostaglandins, steroids, and xenobiotic ketones. This broad specificity allows the enzyme to participate in detoxification, drug metabolism, and signaling molecule turnover. For example, CBR1 reduces prostaglandin E2 to prostaglandin F2alpha, modulating inflammatory responses. It also reduces anthracyclines to less active metabolites, which can reduce drug efficacy in cancer therapy. The same activity is exploited in biocatalysis to produce chiral alcohols with high enantioselectivity.
Key Genes Involved in GO:0004090 carbonyl reductase (NADPH) activity
The following genes and proteins are directly associated with carbonyl reductase (NADPH) activity or its regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CBR1 | Primary human carbonyl reductase; reduces ketones and aldehydes using NADPH | Drug resistance, prostaglandin metabolism, oxidative stress |
| CBR3 | Carbonyl reductase 3; related SDR enzyme with overlapping substrate specificity | Xenobiotic metabolism, cancer drug response |
| AKR1A1 | Aldehyde reductase; reduces aldehydes and ketones with NADPH | Carbonyl detoxification, diabetes complications |
| AKR1B1 | Aldose reductase; reduces glucose and lipid aldehydes | Diabetic complications, inflammation |
| AKR1C1 | 20alpha-hydroxysteroid dehydrogenase; reduces steroids and prostaglandins | Steroid metabolism, cancer |
| AKR1C2 | Type 3 3alpha-hydroxysteroid dehydrogenase; reduces steroids | Steroid hormone regulation |
| AKR1C3 | Prostaglandin F synthase; reduces prostaglandins and steroids | Inflammation, prostate cancer |
| SPR | Sepiapterin reductase; exhibits carbonyl reductase activity | Tetrahydrobiopterin synthesis, neurotransmitter metabolism |
| NQO1 | NAD(P)H:quinone oxidoreductase; reduces quinones | Xenobiotic detoxification, cancer |
| NQO2 | Quinone reductase 2; reduces quinones using NADPH | Oxidative stress, neuroprotection |
| PTGR1 | Prostaglandin reductase 1; reduces prostaglandins | Inflammation, cancer |
| PTGR2 | Prostaglandin reductase 2; reduces prostaglandins | Lipid metabolism |
| DHRS4 | Dehydrogenase/reductase SDR family member 4; reduces carbonyls | Retinoid metabolism, cancer |
| DCXR | Dicarbonyl/L-xylulose reductase; reduces dicarbonyls | Detoxification of reactive carbonyls |
| G6PD | Glucose-6-phosphate dehydrogenase; generates NADPH | Provides reducing power for carbonyl reduction |
| IDH1 | Isocitrate dehydrogenase 1; generates NADPH | Cytosolic NADPH supply |
| IDH2 | Isocitrate dehydrogenase 2; generates NADPH | Mitochondrial NADPH supply |
| ME1 | Malic enzyme 1; generates NADPH | NADPH homeostasis |
How Is carbonyl reductase (NADPH) activity Regulated?
Carbonyl reductase (NADPH) activity is regulated at multiple levels. Transcription of CBR1 can be induced by oxidative stress and xenobiotics through antioxidant response elements, linking its expression to cellular redox status. Post-translational modifications, including phosphorylation and S-nitrosylation, can modulate enzyme activity. The availability of NADPH, generated by the pentose phosphate pathway and malic enzyme, is a key determinant of flux through the reaction. In addition, small-molecule inhibitors such as flavonoids can directly inhibit CBR1 activity, providing a means to regulate the pathway pharmacologically. The enzyme's activity can also be influenced by its oligomeric state and by interactions with other proteins, although these mechanisms are less well characterized.
carbonyl reductase (NADPH) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CBR1 | Cancer drug resistance; anthracycline inactivation | CBR1 knockout cancer cell lines treated with doxorubicin |
| CBR1 | Oxidative stress and neurodegeneration | CBR1 overexpression in neuronal cells exposed to carbonyl stress |
| AKR1C3 | Prostate cancer; prostaglandin metabolism | AKR1C3 knockout prostate cancer cells |
| SPR | Tetrahydrobiopterin deficiency; neurotransmitter disorders | SPR point-mutation models in patient-derived cells |
| NQO1 | Xenobiotic toxicity; cancer susceptibility | NQO1 knockout mice or cells treated with quinones |
Cancer drug resistance
Overexpression of CBR1 and other carbonyl reductases is associated with resistance to anthracycline chemotherapeutics such as daunorubicin and doxorubicin. These enzymes reduce the anthracycline quinone moiety to less active metabolites, reducing drug efficacy. In addition, carbonyl reductase activity can detoxify reactive carbonyls that would otherwise induce apoptosis, further promoting cancer cell survival. Targeting CBR1 with inhibitors is being explored as a strategy to sensitize tumors to chemotherapy.
Neurodegeneration and oxidative stress
Reactive carbonyls accumulate in neurodegenerative diseases such as Alzheimer's and Parkinson's, where they contribute to protein aggregation and neuronal death. Carbonyl reductase (NADPH) activity helps clear these toxic species, and reduced activity may exacerbate pathology. In animal models, enhancing carbonyl reductase activity has been shown to protect against oxidative stress-induced neuronal damage.
Metabolic and inflammatory disorders
Carbonyl reductase activity modulates prostaglandin levels, influencing inflammation and pain. It also participates in steroid hormone metabolism, which is relevant to endocrine disorders. In diabetes, increased carbonyl stress contributes to complications, and carbonyl reductases are part of the defense system.
From carbonyl reductase (NADPH) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CBR1 increase sensitivity to anthracyclines? | CBR1 knockout cell line (e.g., CRISPR-Cas9) |
| Does a specific active-site mutation abolish carbonyl reductase activity? | Point-mutation knock-in of catalytic residues (e.g., Tyr/Lys) |
| Can a tagged CBR1 be used to track subcellular localization? | Knock-in of fluorescent or epitope tag at the endogenous CBR1 locus |
| Does CBR1 overexpression protect against oxidative stress? | CBR1 overexpression cell line or transgenic model |
| Which substrates are metabolized by CBR1 in a cellular context? | CBR1 knockout cells supplemented with candidate carbonyls |
| Can carbonyl reductase activity be redirected to produce a chiral drug intermediate? | Engineered CBR1 variants expressed in E. coli or yeast |
How to Study the carbonyl reductase (NADPH) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADPH absorbance assay | Oxidation of NADPH to NADP+ | Kinetic characterization of carbonyl reductase activity |
| LC-MS/MS | Substrate and product concentrations | Quantifying drug metabolites and prostaglandins |
| RNA-seq | Transcript levels of CBR1 and related genes | Expression profiling under oxidative stress |
| Western blot | Protein expression and modifications | Validating CBR1 overexpression or knockdown |
| X-ray crystallography | Three-dimensional structure of enzyme-cofactor complexes | Active-site mapping and inhibitor design |
| CRISPR knockout screening | Gene essentiality and drug sensitivity | Identifying modifiers of anthracycline response |
| Site-directed mutagenesis | Effect of specific amino acid changes on activity | Probing catalytic residues |
| Isothermal titration calorimetry | Binding affinity for NADPH or substrates | Cofactor binding studies |
Enzymatic activity assays
Carbonyl reductase (NADPH) activity is typically measured spectrophotometrically by monitoring the decrease in NADPH absorbance at 340 nm upon addition of a carbonyl substrate. This assay can be adapted to high-throughput screening for inhibitors or to determine kinetic parameters such as Km and Vmax. For substrates with low turnover, more sensitive methods such as HPLC or LC-MS can quantify product formation.
Gene expression and proteomics
RNA-seq and quantitative PCR can measure CBR1 and related gene expression in response to oxidative stress or drug treatment. Proteomic approaches, including mass spectrometry-based quantification, can assess protein levels and post-translational modifications of carbonyl reductases. These methods help link expression changes to cellular phenotypes.
Structural and biophysical methods
X-ray crystallography and cryo-EM have been used to determine the structure of CBR1 in complex with NADP+ and inhibitors, revealing key active-site residues. Isothermal titration calorimetry and surface plasmon resonance can measure cofactor and substrate binding affinities. These techniques guide the design of point mutations to probe mechanism.
CRISPR-based functional genomics
CRISPR knockout screens can identify genes whose loss alters sensitivity to carbonyl-generating agents or anthracyclines. Pooled libraries targeting carbonyl reductases and related genes can reveal synthetic lethal interactions. Follow-up validation with individual knockouts or point mutations confirms specific roles.
How CRISPR Can Be Used to Study GO:0004090 carbonyl reductase (NADPH) activity
Knockout
CRISPR-Cas9 knockout of CBR1 or related carbonyl reductases can abolish specific enzymatic activities, allowing researchers to test their contribution to drug resistance, oxidative stress survival, and prostaglandin metabolism. Knockout cell lines are valuable for isogenic comparisons and for identifying compensatory pathways.
Point Mutation
Point mutations in catalytic residues such as the conserved tyrosine or lysine of CBR1 can be introduced by CRISPR base editing or homology-directed repair to dissect the mechanism of hydride transfer and proton relay. Such mutants help distinguish between effects on catalysis versus cofactor binding.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins at the endogenous CBR1 locus enables real-time tracking of protein localization and interaction without overexpression artifacts. Knock-in of disease-associated variants can model altered carbonyl reductase activity in patient-derived cells.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of CBR1 can increase carbonyl reductase activity, which is useful for studying protection against carbonyl stress or for enhancing biocatalytic conversion in engineered cells. Overexpression models also help validate drug resistance mechanisms.
How EDITGENE Supports carbonyl reductase (NADPH) activity Research
Researchers studying carbonyl reductase (NADPH) activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as drug resistance or oxidative stress sensitivity. This requires precise genetic models that can isolate the contribution of a single enzyme while avoiding off-target effects. EDITGENE provides a comprehensive suite of CRISPR-based services to generate such models efficiently.
Contact EDITGENE today to design your custom CRISPR model for carbonyl reductase (NADPH) activity research.
Frequently Asked Questions About carbonyl reductase (NADPH) activity
What is carbonyl reductase (NADPH) activity?
It is a molecular function defined by GO:0004090 that catalyzes the NADPH-dependent reduction of ketones and aldehydes to secondary alcohols.
What genes are involved in carbonyl reductase (NADPH) activity?
Key genes include CBR1, CBR3, AKR1A1, AKR1B1, AKR1C1, AKR1C2, AKR1C3, SPR, NQO1, and NQO2, among others.
What is the reaction catalyzed by carbonyl reductase?
The reaction is: a secondary alcohol + NADP+ = a ketone + H+ + NADPH, which is reversible but favors reduction in cells.
How is carbonyl reductase activity measured?
It is commonly measured by monitoring NADPH oxidation at 340 nm or by LC-MS quantification of products.
What diseases are linked to carbonyl reductase (NADPH) activity?
It is linked to cancer drug resistance, neurodegeneration, and inflammatory disorders through its role in drug and prostaglandin metabolism.
Can carbonyl reductase inhibitors be used therapeutically?
Flavonoids and other inhibitors are being studied to modulate CBR1 activity in cancer and oxidative stress conditions.
What is the role of CBR1 in anthracycline resistance?
CBR1 reduces anthracyclines to less active metabolites, reducing drug efficacy and contributing to chemoresistance.
How does NADPH affect carbonyl reductase activity?
NADPH is the essential electron donor; its availability, generated by the pentose phosphate pathway, determines flux through the reaction.
What experimental models are used to study carbonyl reductase?
CRISPR knockout, point mutation, knock-in, and overexpression cell lines, as well as enzymatic assays and structural biology.
Is carbonyl reductase activity used in industrial biocatalysis?
Yes, engineered carbonyl reductases are used to synthesize chiral alcohols such as the vibegron intermediate.
Conclusion
Carbonyl reductase (NADPH) activity (GO:0004090) is a fundamental molecular function that protects cells from reactive carbonyls, modulates drug efficacy, and participates in signaling molecule metabolism. Its broad substrate specificity and central role in redox homeostasis make it a key target for cancer therapy, anti-inflammatory strategies, and industrial biocatalysis. Understanding its mechanism, regulation, and disease links requires precise genetic models and robust enzymatic assays. EDITGENE's CRISPR services provide the tools needed to dissect this activity in any cell type, accelerating discoveries in metabolism, pharmacology, and synthetic biology.
References
- 1. Barracco V et al.. 2020. Dehydrogenase/reductase activity of human carbonyl reductase 1 with NADP(H) acting as a prosthetic group.. Biochem Biophys Res Commun 522(1):259-263 PMID: 31759632
- 3. Sueoka T et al.. 1985. Carbonyl reductase activity of sepiapterin reductase from rat erythrocytes.. Biochim Biophys Acta 843(3):193-8 PMID: 3904835
- 4. Merk H et al.. 1991. Induction and inhibition of NAD(P)H: quinone reductase in murine and human skin.. Skin Pharmacol 4(3):183-90 PMID: 1768430
- 5. Penning TM et al.. 2021. Aldo-Keto Reductases and Cancer Drug Resistance.. Pharmacol Rev 73(3):1150-1171 PMID: 34312303
- 6. Endo S et al.. 2026. Carbonyl reductase 1: A redox-regulating carbonyl detoxification enzyme in health and disease.. Chem Biol Interact 439:112315 PMID: 42674267
- 7. Arai Y et al.. 2015. Structure-activity relationship of flavonoids as potent inhibitors of carbonyl reductase 1 (CBR1).. Fitoterapia 101:51-6 PMID: 25549925
- 8. Zhang XJ et al.. 2025. Stability and Activity Collaborative Improvement of Carbonyl Reductase Based on the Modification Strategy for Transition Zone of the Flexible and Rigid Regions: An Application for Vibegron Chiral Intermediate Synthesis in High Efficiency.. J Agric Food Chem 73(29):18353-18365 PMID: 40629745
